Want to see HK:2325 full AI Analyst Report?
2325 Stock Chart & Stats
HK$0.99
HK$0.00(0.00%)
At close: 4:00 PM EST
HK$0.99
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$0.44 - HK$2.10
Previous CloseN/A
Volume10.00K
Average Volume (3M)291.15K
Market Cap
HK$288.88M
Enterprise Value-HK$727.76M
Total Cash (Recent Filing)HK$1.64B
Total Debt (Recent Filing)HK$688.17M
Price to Earnings (P/E)3.9
Beta0.16
Next Earnings
Mar 31, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.2%
Share Statistics
EPS (TTM)0.10
Shares Outstanding621,250,500
10 Day Avg. Volume165,450
30 Day Avg. Volume291,150
Financial Highlights & Ratios
PEG Ratio-1.77
Price to Book (P/B)0.45
Price to Sales (P/S)0.87
P/FCF Ratio2.11
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.01
Revenue Forecast (FY)HK$884.18M
Bulls Say, Bears Say
Bulls Say
Cash GenerationStrong operating and free cash flow provide internal funding for ongoing operations and selective investment. The improvement across 2023–2025 suggests better cash conversion and financial resilience, although continued consistency will determine how durable this advantage becomes.
Operating ReboundThe 2025 operating rebound shows that the business can restore operating profitability after the severe earnings reset of 2023–2024. If maintained, improved EBIT performance could support cash generation, operational flexibility, and a more stable earnings base over the next several quarters.
Balance Sheet RepairLower leverage versus 2024 reduces balance-sheet pressure and indicates some financial repair. A sizable equity base also provides a buffer against operating volatility, giving management more flexibility to sustain the business while rebuilding growth and profitability.
Bears Say
Revenue ContractionThree consecutive years of falling revenue indicate a materially smaller business base and weak underlying momentum. Persistent contraction can reduce operating leverage, limit reinvestment capacity, and make the 2025 margin recovery harder to sustain without renewed demand and revenue stabilization.
Weak ProfitabilityThe return to profitability remains shallow, with negligible net margin and very low shareholder returns following substantial losses. This unstable bottom line provides limited protection against renewed operating pressure and makes long-term earnings power difficult to establish.
Elevated LeverageAlthough leverage improved from 2024, debt relative to equity remains meaningfully above earlier levels. The higher capital burden can constrain future financial flexibility and increase sensitivity to further revenue weakness while profitability and returns remain under pressure.
Yunkang Group Limited News
2325 FAQ
What was Yunkang Group Limited’s price range in the past 12 months?
Yunkang Group Limited lowest stock price was HK$0.44 and its highest was HK$2.10 in the past 12 months.
What is Yunkang Group Limited’s market cap?
Yunkang Group Limited’s market cap is HK$288.88M.
When is Yunkang Group Limited’s upcoming earnings report date?
Yunkang Group Limited’s upcoming earnings report date is Mar 31, 2027 which is in 175 days.
How were Yunkang Group Limited’s earnings last quarter?
Yunkang Group Limited released its earnings results on Aug 28, 2026. The company reported HK$0.005 earnings per share for the quarter.
Is Yunkang Group Limited overvalued?
According to Wall Street analysts Yunkang Group Limited’s price is currently Overvalued.
Does Yunkang Group Limited pay dividends?
Yunkang Group Limited pays a Annually dividend of HK$0.02 which represents an annual dividend yield of 0.2%. See more information on Yunkang Group Limited dividends here
What is Yunkang Group Limited’s EPS estimate?
Yunkang Group Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Yunkang Group Limited have?
Yunkang Group Limited has 621,250,500 shares outstanding.
What happened to Yunkang Group Limited’s price movement after its last earnings report?
Yunkang Group Limited reported an EPS of HK$0.005 in its last earnings report. Following the earnings report the stock price went down -3.361%.
Which hedge fund is a major shareholder of Yunkang Group Limited?
Currently, no hedge funds are holding shares in HK:2325
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Yunkang Group Limited Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-64.45%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-7.23%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Yunkang Group Limited
Yunkang Group Limited, established in 2008 and headquartered in Guangzhou, People's Republic of China, operates as a comprehensive provider of medical operational services. The company offers a wide range of diagnostic testing solutions to medical institution alliances, which encompass assisting with the setup and enhancement of diagnostic centers, developing standard operating procedures for testing, delivering expert diagnostic consultations and staff training, sourcing necessary equipment, implementing smart Internet of Things technology, and providing logistics support. For diagnostic outsourcing, Yunkang Group conducts diverse tests, including pathology examinations; infectious disease diagnostics for conditions such as hepatitis B, tuberculosis, human papillomavirus, Epstein-Barr virus, rabies, and respiratory pathogens (via nucleic acid testing); genetic and reproductive health screenings; and routine diagnostic assessments for chronic ailments like kidney, blood, autoimmune, and endocrine metabolic diseases. Furthermore, the company caters to financial institutions and insurance firms by offering personalized diagnostic testing, medical report interpretation, and hospital referral services. Yunkang Group's capabilities also extend to information technology, medical logistics, procurement of medical equipment, healthcare technology development, and various project investments. These services are delivered through its network of independent clinical laboratories and integrated on-site diagnostic facilities.
Technical Analysis
EC Healthcare
―
Mediwelcome Healthcare Management & Technology Inc.
―
Yonghe Medical Group Co., Ltd.
―
Hospital Corporation of China Ltd
―
Town Health International Medical Group Ltd.
―